Vis børsmeldingen
patent covering the use of Alpha37 for the treatment of Chronic Lymphocytic
Leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). Alpha37 is an investigational
radioimmunoconjugate developed by Nordic Nanovector in collaboration with Orano
Med comprising a proprietary chimeric CD37-targeting antibody conjugated to the
alpha-particle generating radionuclide lead-212.
Alpha37 has completed preclinical development, during which it demonstrated
promising immunogenicity, biodistribution and targeted tumour-cell killing
results in preclinical lymphoma and leukaemia models. Preclinical data presented
at international cancer congresses during the past year have shown that a single
injection of Alpha37 is well-tolerated and produces a promising anti-cancer
effect and subsequent improvement on survival in preclinical models of CD37
-positive CLL and NHL.
Jostein Dahle, CSO of Nordic Nanovector, said: “We are pleased to receive this
patent protection for Alpha37 in the European Union. We view Alpha37 as a
complementary candidate to Betalutin® based on its differentiated therapeutic
profile and potential to treat CLL and NHL. Our preclinical Alpha37 programme
represent a pipeline asset that leverages our strong expertise in
radioimmunoconjugates.”
EU patent no. 3272364, which is entitled “Chimeric Therapeutic Antibodies” will
be active until 2032 with the option of prolonging for five 5 additional years.
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
Forward-looking statements
This press release contains certain forward-looking statements. These
statements are based on management’s current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.
This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.
Kilde
.
